Document is current
Any future updates will be listed below
-
Authors
Yuan, Chen https://orcid.org/0000-0002-0708-9648
Renfro, Lindsay
Ambadwar, Pratibha B.
Ou, Fang-Shu
McLeod, Howard L.
Innocenti, Federico
Meyerhardt, Jeffrey A.
Wolpin, Brian M.
Goldberg, Richard M.
Grothey, Axel
Fuchs, Charles S.
Ng, Kimmie
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (U10CA180821, U10CA180882)
- License Information
-
More Information
Article History
Received: 25 September 2018
Accepted: 11 May 2019
First Online: 18 May 2019
Compliance with ethical standards
:
: Charles S. Fuchs declares consulting for Agios, Bain Capital, Bayer, Celgene, Dicerna, Eli Lilly, Entrinsic Health, Five Prime Therapeutics, Genentech, Gilead Sciences, KEW, Merck, Merrimack Pharmaceuticals, Pfizer, Sanofi, Taiho, and Unum Therapeutics. He also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX Therapeutics and Entrinsic Health. Other authors declare that they have no conflict of interest.
